Suppr超能文献

韩国 BRCA1/2 突变阴性遗传性乳腺癌高危患者中癌症易感性基因的变异。

Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.

机构信息

Hereditary Cancer Clinic, Cancer Prevention Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

出版信息

BMC Cancer. 2018 Jan 16;18(1):83. doi: 10.1186/s12885-017-3940-y.

Abstract

BACKGROUND

We evaluated the incidence and spectrum of pathogenic and likely pathogenic variants of cancer susceptibility genes in BRCA1/2 mutation-negative Korean patients with a high risk for hereditary breast cancer using a comprehensive multigene panel that included 35 cancer susceptibility genes.

METHODS

Samples from 120 patients who were negative for BRCA1/2 mutations, but had been diagnosed with breast cancer that was likely hereditary, were prospectively evaluated for the prevalence of high-penetrance and moderate-penetrance germline mutations.

RESULTS

Nine patients (7.5%) had at least one pathogenic or likely pathogenic variant. Ten variants were identified in these patients: TP53 in two patients, PALB2 in three patients, BARD1 in two patients, BRIP1 in two patients, and MRE11A in one patient. We also identified 30 types of 139 variants of unknown significance (VUS). High-penetrance germline mutations, including TP53 and PALB2, tended to occur with high frequency in young (< 35 years) breast cancer patients (4/19, 21.1%) than in those diagnosed with breast cancer at ≥35 years of age (1/101, 1.0%; p = 0.003).

CONCLUSIONS

These combined results demonstrate that multigene panels offer an alternative strategy for identifying veiled pathogenic and likely pathogenic mutations in breast cancer susceptibility genes.

摘要

背景

我们使用包含 35 个癌症易感基因的综合多基因panel,评估了 BRCA1/2 突变阴性、遗传性乳腺癌风险高的韩国患者中癌症易感基因的致病性和可能致病性变异的发生率和谱。

方法

前瞻性评估了 120 例 BRCA1/2 突变阴性但被诊断为可能遗传性乳腺癌的患者样本中高外显率和中外显率种系突变的流行情况。

结果

9 名患者(7.5%)至少有一种致病性或可能致病性变异。在这些患者中发现了 10 种变异:2 名患者 TP53 突变,3 名患者 PALB2 突变,2 名患者 BARD1 突变,2 名患者 BRIP1 突变,1 名患者 MRE11A 突变。我们还鉴定了 30 种 139 种意义不明的变异(VUS)。高外显率种系突变,包括 TP53 和 PALB2,在年轻(<35 岁)乳腺癌患者(4/19,21.1%)中比在年龄≥35 岁诊断为乳腺癌的患者(1/101,1.0%;p=0.003)中更频繁地发生。

结论

这些综合结果表明,多基因panel 为鉴定乳腺癌易感基因中隐匿性致病性和可能致病性突变提供了一种替代策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b54/5769462/305b92126999/12885_2017_3940_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验